Trials / Active Not Recruiting
Active Not RecruitingNCT05768711
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
Phase II Study With Safety run-in of Azacitidine (AZA) Combined With Venetoclax (VEN) in Patients With Higher-risk Chronic Myelomonocytic Leukemia (CMML)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Groupe Francophone des Myelodysplasies · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of Azacitidine combined with Venetoclax in patients with higher-risk chronic myelomonocytic leukemia
Detailed description
AVENHIR trial is an open-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of the combination of Azacitidine and Venetoclax in, hypomethylating agent-naïve, higher-risk chronic myelomonocytic leukemia patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Venetoclax | Combination of Azacitidine and Venetoclax |
Timeline
- Start date
- 2023-10-04
- Primary completion
- 2026-05-01
- Completion
- 2028-10-01
- First posted
- 2023-03-14
- Last updated
- 2026-03-05
Locations
24 sites across 1 country: France
Source: ClinicalTrials.gov record NCT05768711. Inclusion in this directory is not an endorsement.